Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication.

To analyse through a large multicentre series, morbidity of nephron-sparing surgery (NSS) in relation to tumour size and surgical indication.
The study included patients from eight international academic centres. Age, sex, TNM stage, tumour size, Fuhrman grade, Eastern Cooperative Oncology Group performance status (ECOG-PS), surgical margins, local and distant recurrences, and overall and cancer-specific survival rates were collected and analysed. Indication for elective or mandatory NSS, medical and surgical complication rates, mean blood loss, blood transfusion, and length of hospital stay were specifically recorded for the purpose of this study. Groups were compared for qualitative and quantitative variables by using chi(2) (Fischer exact test) and Student t tests, respectively.
A total of 1048 NSS procedures were included in this study. Mean tumour size was 3.4+/-2.1cm. In 730 elective procedures mean operative time (p=0.002), mean blood loss (p=0.01), the need for blood transfusion (p=0.001), and urinary fistula rate (p=0.01) were significantly increased for tumours >4 cm. However, these differences did not result in significantly increased medical (p=0.4), surgical complication rates (p=0.6), or length of hospital stay (p=0.9). Finally, in elective procedures for malignant tumours, positive surgical margins, local or distant recurrence rates, and cancer-specific survival were not significantly different in tumours < or =4 cm and >4 cm.
Excellent cancer control and outcomes can be achieved with NSS in carefully selected patients with tumours >4 cm. Expanding the size indication of elective NSS results in an increased but acceptable morbidity.
AuthorsJean-Jacques Patard, Allan J Pantuck, Maxime Crepel, John S Lam, Laurent Bellec, Baptiste Albouy, David Lopes, Jean-Christophe Bernhard, François Guillé, Bertrand Lacroix, Alexandre De La Taille, Laurent Salomon, Christian Pfister, Michel Soulié, Jacques Tostain, Jean-Marie Ferriere, Claude C Abbou, Marc Colombel, Arie S Belldegrun
JournalEuropean urology (Eur Urol) Vol. 52 Issue 1 Pg. 148-54 (Jul 2007) ISSN: 0302-2838 [Print] Switzerland
PMID17240036 (Publication Type: Journal Article, Multicenter Study)
  • California (epidemiology)
  • Carcinoma, Renal Cell (epidemiology, pathology, surgery)
  • Female
  • Follow-Up Studies
  • France (epidemiology)
  • Humans
  • Kidney Neoplasms (epidemiology, pathology, surgery)
  • Length of Stay (statistics & numerical data)
  • Male
  • Middle Aged
  • Morbidity (trends)
  • Neoplasm Staging
  • Nephrectomy (methods)
  • Nephrons (surgery)
  • Prognosis
  • Retrospective Studies
  • Survival Rate (trends)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: